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Foot-and-mouth  disease  (FMD)  is  present  in  much  of  Turkey  and its control  is largely  based  on  vaccination.
The  arrival  of  the FMD  Asia-1  serotype  in  Turkey  in  2011  caused  particular  concern,  spreading  rapidly
westwards  across  the  country  towards  the  FMD free  European  Union.  With  no  prior  natural  immunity,
control  of  spread  would  rely heavily  on  vaccination.
Unlike  human  vaccines,  field  protection  is  rarely  evaluated  directly  for FMD vaccines.  Between
September  2011  and  July  2012  we  performed  four  retrospective  outbreak  investigations  to  assess  the  vac-
cine effectiveness  (VE)  of FMD  Asia-1  vaccines  in  Turkey.  Vaccine  effectiveness  is  defined  as  the  reduction
in risk  in  vaccinated  compared  to unvaccinated  individuals  with  similar  virus  exposure  in  the  field.
The four  investigations  included  12  villages  and  1230  cattle  >4 months  of  age.  One  investigation
assessed the FMD Asia-1  Shamir  vaccine,  the  other  three  evaluated  the  recently  introduced  FMD  Asia-1
TUR  11  vaccine  made  using  a field  isolate  of the  FMD  Asia-1  Sindh-08  lineage  that had  recently  entered
Turkey.
After  adjustment  for  confounding,  the  TUR  11  vaccine  provided  moderate  protection  against  both
clinical  disease  VE  = 69% [95%  CI: 50%–81%]  and  infection  VE = 63%  [95%  CI: 29%–81%].  However,  protection
was  variable  with  some  herds  with  high  vaccine  coverage  still experiencing  high  disease  incidence.  Some
of this  variability  will  be the  result  of  the variation  in virus  challenge  and  immunity  that  occurs  under
field  conditions.
In the  outbreak  investigated  there  was  no  evidence  that  the  Asia-1  Shamir  vaccine  provided  adequate
protection  against  clinical  FMD  with  an  incidence  of 89%  in single  vaccinated  cattle  and  69%  in  those
vaccinated  two to  five  times.
Based  on  these  effectiveness  estimates,  vaccination  alone  is  unlikely  to  produce  the  high  levels  of  herd
immunity  needed  to control  FMD without  additional  control  measures.. Introduction
Foot-and-mouth disease (FMD) vaccines are used on an enor-
ous scale across the globe, with over 2 billion doses thought
o be used every year [1]. Despite this, little is done to assess
heir performance in the field. Vaccine effectiveness, defined as
he reduction in risk in vaccinated individuals compared to sim-
larly exposed unvaccinated individuals under field conditions [2],
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provides a direct measure of vaccine protection within a vaccina-
tion programme.
FMD  in Anatolian Turkey (Fig. 1) poses a threat to the EU which is
disease free [3]. During 2009–11 (inclusive) approximately twenty-
million doses of polyvalent FMD  vaccine were used a year for
biannual mass vaccination of Turkey’s cattle population [4]. In
Turkey, inactivated, oil adjuvanted FMD  vaccines with a specified
protective effect of >3PD50 (PD50 = 50% protective dose) are admin-
istered intra-muscularly.
In 2011 Turkey experienced an incursion of the FMD  Asia-1
serotype. Although serotypes A and O are endemic this serotype
had not been present since 2002 [5]. Vaccine matching tests sug-
gested that the vaccine used at the time (Asia-1 Shamir) would not
protect against the new field strain (FMD Asia-1 Sindh-08) [6]. In
T.J.D. Knight-Jones et al. / Vaccine 32 (2014) 1848–1855 1849
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aig. 1. Map  showing locations of foot-and-mouth disease outbreaks investigated. 1
012  (n = 218); 3) Denizli province, Turkey June 2012 (n = 405) and 4) Afyon provin
nvestigations 2–4) investigated the new FMD  Asia-1 TUR 11 vaccine (Sindh-08 stra
ight of this and the rapid spread of the Asia-1 virus across most of
urkey, the S¸ ap institute, the Turkish FMD  research institute and
accine producer, changed their Asia-1 vaccine strain from Shamir
o an isolate of the circulating Sindh-08 field virus (the vaccine is
eferred to as the TUR 11 vaccine). In this study, we  investigated
MD  Asia-1 vaccine effectiveness for both the TUR 11 and Shamir
accine through retrospective outbreak investigations.
. Materials and methods
Four retrospective outbreak investigations were conducted
etween September 2011 and July 2012. The investigations exam-
ned cattle in village small holdings. Suitable village outbreaks were
dentified from central records with the assistance of local veteri-
ary services. Villages eligible for the study fulfilled the following
riteria:
 A recent FMD  Asia-1 outbreak had been reported.
 The outbreak had recently finished or was in the tail end of the
epidemic. The course of an outbreak was determined from oral
accounts from villagers and state veterinarians who  visited the
outbreaks repeatedly. An outbreak was deemed to be in the tail
end if few or no new cases were detected the week before the
investigation.
 The Asia-1 vaccines under investigation had been used in the vil-
lage within the six months prior to the outbreak, i.e. trivalent FMD
vaccine against serotypes A, O and either Asia-1 Shamir or Asia-1
TUR 11 produced by the S¸ ap institute, Ankara, Turkey.
The outbreaks investigated were the only ones found at the time
hat fitted the criteria. Investigated villages also complied with the
ollowing:
 They had no history of prior exposure to FMD  Asia-1.
 Farmers could recall which cattle were vaccinated (e.g. farmers
had few cattle or a consistent vaccination routine).
 Farmers were aware of which animals developed FMD.
Details of the four investigations are presented in Table 1 and
ig. 1.
.1. Sampling and data collectionEach investigation lasted for approximately eight days. Each vil-
age was visited by the investigation team (Knight-Jones and Bulut
lus an assistant). Details of livestock management, vaccination
nd FMD  history were gathered for the village. Then, householdshan province, Turkey September 2011 (n = 296); 2) Afyon province, Turkey January
rkey July 2012 (n = 311). Investigation 1) looked at the FMD  Asia-1 Shamir vaccine.
with known FMD  virus exposure were sampled, i.e. those with
cases or known contact with cases. If there was insufficient time
to include all eligible households, equal proportions of households
were selected from different geographic sections of the village.
Within households, FMD  vaccination and clinical history were col-
lected for each animal. Animals were blood sampled and received
an oral examination examining the hard palate, gums, lips and
tongue (extruded) except when impossible or unsafe.
Oral vesicles and blisters typically appear about four days after
infection. They typically heal within 10 days, leaving a scar that
becomes less visible over time, although foci lacking lingual papil-
lae may  be visible for weeks [7]. As appearance of clinical signs
is strongly correlated with shedding and transmission, this is a
relevant outcome for assessing vaccine protection.
Full details of data collected are provided in table S1 (supple-
mentary material).
2.2. Analysis
All analysis was  done at the individual animal level unless stated
otherwise. An animal was  considered affected by FMD if detected
on examination or seen by the farmer. All farmers were familiar
with FMD. Vaccination status refers to whether an animal was  vac-
cinated at the previous round of mass vaccination (done within the
last six months). In the TUR 11 investigations, aside from the single
round of vaccination with the trivalent A, O, Asia-1 TUR 11 vac-
cine, earlier FMD  vaccination only included A and O strains. In the
Shamir vaccine investigation (Ardahan province, Eastern Turkey),
animals had been repeatedly vaccinated with the Asia-1 Shamir
vaccine every six months. In this latter investigation FMD  risk by
number of doses received in an animal’s life was also evaluated.
2.3. Validation
2.3.1. FMD status
Farmer reported FMD  status was  compared to findings from
clinical examination to assess the sensitivity and specificity of
farmer detection. FMD  status (farmer reported or detected on
examination) was  compared to NSP sero-status, since convalescent
animals should be NSP sero-positive.
2.3.2. Vaccination status
True vaccine status, as recorded by the government vaccina-
tor at the time of vaccination was compared to farmer reported
vaccination status. Government records were not available for all
villages.
1850 T.J.D. Knight-Jones et al. / Vaccine 32 (2014) 1848–1855
Table 1
Details of the four vaccine effectiveness studies performed in Turkey.
Investigation
Investigation dates
No. of
villages
Village livestock
population
Husbandry Management
groups sampled
FMD  Asia-1
vaccine
Time between
vaccination & outbreak
Date outbreak
started
Ardahan province
27–30 September 2011
6 450–3000 cattle
0–300 sheep
Extensive
grazing
16 Shamir 62–152 days 19 June – 24
September 2011
Afyon  province-1
9–14 January 2012
2 700–2300 cattle
0–4000 sheep
Always housed 19 TUR 11 48–65 days 20 & 22 November
2012
Denizli province
26 June – 1 July 2012
2 470–550 cattle
400–1000 sheep
Housed and
grazing
75 TUR 11 39–126 days 26–29 May  2012
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bAfyon  province-2
10–13 July 2012
2 2000 cattle
1000–1500 sheep
Housed and
grazing
.4. Vaccine effectiveness
To remove the effect of maternally-derived-immunity, all
nimals under five months were excluded from the analysis.
escriptive data analysis was performed. Crude vaccine effective-
ess, VE, was calculated as:
E = 1 −
RV
RU
(1)
here RV and RU are the attack rates (percentage affected) in
he vaccinated and unvaccinated populations, respectively. Uni-
ariable analysis of potential risk factors for clinical FMD  was
erformed. As crude VE estimates, not adjusted for confounding,
an be misleading, VE was calculated whilst adjusting for one fac-
or at a time by stratification, see Table 2 with more detailed results
n table S2 (a) and (b).
.5. Regression modelling
To simultaneously adjust for several confounders, a multilevel,
ultivariable, binomial regression modelling was constructed
sing a complementary log–log link function. To account for the
ierarchical structure of the data a random intercept was included,
arying by village and management group nested within village.
his class of model provides estimates of the log of the rate ratio
8] that can be used to determine VE using Eq. (1). Regression
odelling was carried out in a Bayesian framework to allow for
ncertainty in the time-at-risk for each animal.
.6. Model building
A forward fitting approach was used adding vaccine status
o the model first followed by the other exposures in order
f decreasing univariable strength of association with the out-
ome. A factor was retained if it improved model fit or removed
onfounding. All two way interactions were investigated. Non-
nformative prior distributions were used (diffuse normal for
egression coefficients and uniform for the standard deviation of
andom effects). Squared standardised deviance residuals were
ssessed and a global goodness-of-fit Bayesian p-value calculated
sing posterior predictive checking [9].
.7. Time at risk
A time offset was included in the model representing time-
t-risk, though this was not directly observed. To incorporate
ncertainty in the time-at-risk, this parameter was sampled from
 uniform distribution with minimum and maximum values as fol-
ows: for non-cases, the minimum was the number of days between
he start of the village outbreak and the investigation and the
aximum was the number of days between last vaccination and
he investigation. For those with FMD, time at risk ended halfway
etween the time of the outbreak and the investigation for both theTUR 11 65–85 days 13 June 2012
minimum and maximum. This represented the average time when
a case would become affected.
2.8. Outcomes
The model was also used to estimate VE against severe disease,
i.e. severe enough for an animal to stop eating or where oral lesions
had a combined diameter of greater than 50% of the width of the
hard palate (approximately).
VE against infection was calculated. An animal was considered
infected during the outbreak if it tested positive for both NSP anti-
bodies (>50% percentage inhibition, standard cut off) and Asia-1
structural protein (SP) antibodies (reciprocal titre >32, standard
cut off), the former tested using the PrioCHECK FMDV NS ELISA
(Prionics, Zurich, Switzerland) and the latter by titration with the
Asia-1 Liquid Phase Blocking ELISA (The Pirbright Institute, UK).
There is some uncertainty over the relative reactivity of the LPB
ELISA, which uses the Asia-1 Shamir antigen, with cattle vaccinated
with the Shamir vaccine and infected or vaccinated with the Sindh-
08 strain. The possibility of low sensitivity due to differences in the
field virus and the ELISA antigen provided a further reason for using
the 1:32 titre cut-off and not higher. Testing was performed at the
S¸ ap institute, Ankara, Turkey.
The relationship between within-group incidence and within-
group vaccine coverage was investigated.
Preliminary analysis was done in R [10] with the lme4 package
[11], while the Bayesian analysis was  implemented in OpenBUGS
[12].
2.9. Vaccine match and batch release testing
Vaccine matching tests had previously been done at WrlFMD. r1-
Values were 0.13–0.27 for the Shamir vaccine and >0.81 for the TUR
11 vaccine with the Sindh-08 field strain (an r1-value <0.3 suggests
poor vaccine match) [6].
All vaccine batches are routinely tested to ensure that they elicit
an “adequate” immune response. Tested at point of production in
five cattle, 28 days after vaccination with a single dose, cattle had
a mean virus neutralisation reciprocal titre of 24 for both vaccine
batches used at Ardahan and Denizli, 29 for the batch used in Afyon-
1 and 34 for the two  batches used at Afyon-2 (assessed against
vaccine homologous virus). The cut-off titre for protection found in
challenge studies was 16 (as per OIE guidelines [13]).
Post-vaccination immune response was  also assessed during the
investigations in cattle not affected by or exposed to FMD.
3. ResultsIn total, 1377 cattle were included in the study of which 1230
were over four months of age. The cattle included in the four
investigations were from 134 management groups from 97 differ-
ent holdings in 12 villages. Typically, almost all households in a
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Table 2
Descriptive statistics, categorical univariable association of risk factors with clinical FMD  and stratum specific vaccine effectiveness for the TUR 11 vaccinated animals only except where indicated. Animals over four months only.
Variable Category % in each
category
Cases/Total Chi-squared
p-value
Unvaccinated
cattle
Cases/Total
Vaccinated cattle Cases/Total TUR  11 Vaccine effectiveness (95% CI)
Unvaccinated taken from all studies
TUR  11 Shamir
Age (months) n = 1230 4–6 11% 90/132 (68%) p < 0.001 27/47 (57%) 18/37 (49%) 45/48 (94%) 15% (−28% to 44%)
7–18  31% 224/381 (59%) 74/111 (67%) 77/189 (41%) 73/81 (90%) 40% (15%–51%)
18–36  33% 192/406 (47%) 74/127 (58%) 66/212 (33%) 52/77 (68%) 44% (28%–56%)
>36  25% 108/311 (35%) 34/81 (42%) 53/176 (30%) 21/54 (39%) 28% (0%–49%)
Common grazing
n  = 1230
Yes 56% 405/693 (58%) p = 0.02 52/73 (71%) 165/371 (44%) 188/249 (76%) 38% (22%–51%)
No  44% 209/537 (39%) 157/293 (54%) 49/233 (21%) 3/11 (27%) 61% (50%–70%)
Breed  n = 1100 Black & white 45% 228/496 (46%) p < 0.001 93/139 (67%) 135/357 (38%) – 44% (31%–53%)
Continental 23% 123/250 (49%) 34/61 (56%) 14/42 (33%) 154/195 (79%) 27% (1%–46%)
Local  32% 223/354 (63%) 55/117 (47%) 55/135 (41%) 34/54 (63%) 29% (−13% to 57%)
Sex  n = 1229 Male 29% 207/352 (59%) p < 0.001 101/145 (70%) 48/143 (34%) 58/64 (91%) 52% (39%–62%)
Female  71% 406/877 (46%) 108/221 (49%) 166/461 (36%) 132/195 (68%) 26% (11%–39%)
Trimester (>14 months
age only) n = 277
Not pregnant 44% 43/122 (35%) p = 0.3 5/14 (36%) 38/108 (35%) – 1% (−107% to 53%)
First  25% 18/69 (26%) 6/14 (43%) 12/55 (23%) – 49% (−11% to 77%)
Second  16% 10/44 (23%) 2/4 (50%) 8/40 (20%) – 60% (−27% to 87%)
Third  15% 10/42 (24%) 0/3 (0%) 10/39 (26%) – –
Management group
size (cattle) n = 1230
<11 12% 67/143 (47%) p = 0.09 33/52 (63%) 31/80 (39%) 3/11 (27%) 39% (11%–58%)
11–20  32% 193/396 (49%) 129/182 (71%) 64/214 (30%) 58% (48%–66%)
21–30  8% 59/98 (62%) 7/27 (26%) 52/68 (76%) −195% (−)
>30  48% 295/596 (49%) 40/105 (38%) 67/242 (28%) 188/249 (76%) 27% (0%–47%)
Time  between
vaccination and
outbreak n = 864
39–50 days 41% 130/339 (38%) p < 0.0001 – 127/328 (39%) 3/11 (27%) –
51–100  days 43% 170/379 (45%) – 80/267 (30%) 90/112 (80%) –
101–152  days 16% 105/146 (72%) – 7/9 (78%) 98/137 (72%) –
Herd  vaccine coverage
n  = 1230
0 22% 144/270 (53%) p = 0.02 144/270 (53%) – – –
1%–39%  5% 36/56 (64%) 31/45 (69%) 3/8 (38%) 2/3 (67%) 46% (−36% to 79%)
40%–69%  4% 23/46 (50%) 11/18 (61%) 0/5 (0%) 12/23 (52%) 15% (−72% to 58%)
70%–94%  14% 77/174 (44%) 21/29 (72%) 41/126 (33%) 15/19 (79%) 58% (39%–71%)
>94%  56% 334/684 (49%) 2/4 (50%) 170/465 (37%) 162/215 (75%) 26% (−3% to 100%)
Investigation n = 1230 Ardahan 24% 207/296 (70%) p < 0.001 19/47 (40%) – 188/249 (76%) −87% (−144% to −44%) Shamir
Afyon-1 18% 78/218 (36%) 64/127 (50%) 11/80 (14%) 3/11 (27%) 73% (56%–84%)
Denizli  33% 189/405 (47%) 55/68 (81%) 134/337 (40%) – 51% (38%–61%)
Afyon-2 25% 140/311 (45%) 71/124 (57%) 69/187 (37%) – 36% (17%–50%)
Total  100% 614/1230 (50%) 209/366 (57%) 214/604 (35%) 191/260 (73%) –
1852 T.J.D. Knight-Jones et al. / Vaccine 32 (2014) 1848–1855
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After multiple doses of the Shamir vaccine, risk of FMD  fell from
89% in single vaccinated cattle to 40% in those with more than five
doses over their lifetime (see Table 3).
Table 3
The risk of clinical FMD  by number of doses of the FMD Asia-1 Shamir vaccine
received in an animal’s lifetime. All cattle were over four months old and number
of  vaccine doses is highly correlated with age. NB: in the TUR 11 vaccine investiga-
tions animals had only received a maximum of one dose as this was a new vaccine.
Furthermore these cattle had never previously been vaccinated for FMD  Asia-1.
Number of vaccine doses in lifetime Incidence risk Relative risk
Cases/total [95% CI]Fig. 2. Population pyramids showing numbers of cattle s
illage would own some cattle (inter-quartile range 5–15 cattle per
olding). See Fig. 2 for the age-sex structure.
Oral examination was performed on 82% (611/742) of cat-
le ≤24 months and 42% (207/488) of cattle >24 months of age.
ll (724/724) cattle ≤24 months were blood sampled and 99%
484/488) of those >24 months.
The percentage of cattle over four months old with clinical FMD
anged between 36% and 70%, depending on the investigation. The
roportion infected (NSP positive with Asia-1 SP titre ≥32) was 86%
n the unvaccinated (222/257), 65% in the TUR 11 vaccinated cattle
211/327) and 89% in the Shamir vaccinated cattle (129/145).
Vaccine coverage of animals over four months was  84% (Ardahan
nvestigation), 42% (Afyon-1 investigation), 83% (Denizli investiga-
ion) and 60% (Afyon-2 investigation). The Shamir vaccine was only
sed in the Ardahan investigation except for eleven cattle in the
fyon-1 investigation.
Table 2 shows both descriptive statistics and univariable asso-
iations with clinical FMD  with more details in table S2 (a) and
b). All factors except trimester of pregnancy (p = 0.3) showed some
egree of association with clinical FMD  (p < 0.1) (i.e. vaccination sta-
us, age, use of common grazing, breed, sex, herd size, time since
accination, herd vaccine coverage and the investigation).
.1. Validation
.1.1. FMD  status
Of the 394 animals with clinical FMD  on examination, farmers
eported disease in 283 (detection sensitivity of 72%). This showed
ittle variation with herd size (p = 0.1). Failure to detect FMD  will
esult from mild disease or limited farmer observation and recall.Cases where the farmer reported disease but clinical signs were
ot apparent on examination (47/371 [13%]) will result from recov-
ry or recall error. The remaining 87% where both the farmer and
he examination did not detect disease gives a pessimistic estimated in the four investigations broken down by age and sex.
of farmer specificity. Detection rates were similar for vaccinated
and unvaccinated cattle (p = 0.6), so misdiagnosis should not bias
vaccine effectiveness estimates.
3.1.2. Vaccine status
Accurate government vaccine records were available for 372
animals. From these, 280/287 were correctly reported as vacci-
nated by the farmer (98% accuracy [95% CI = 95%–99%]). This error
rate was  unaffected by FMD  status (p = 0.25). Farmer reporting was
correct for 83/85 unvaccinated cattle (98% [95% CI = 92%–100%]).
Again, FMD  status did not affect this misclassification (p = 0.14).
After exclusion of young calves, only one vaccinated and one unvac-
cinated animal were misclassified from 263 vaccinated and 57
unvaccinated cattle.
3.2. Multiple vaccine doses – Shamir only0 14/21 (67%) 0.75 [0.59–0.96]
1  102/115 (89%) Baseline
2–5  58/84 (69%) 0.78 [0.67–0.9]
≥6  18/45 (40%) 0.45 [0.35–0.58]
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.3. Crude VE
Crude estimates for VE are presented stratified by different vari-
bles (Table 2), according to different clinical outcomes (table S3)
nd for infection assessed by different serological criteria (table S4).
owever, due to confounding limited conclusions can be drawn
rom crude VE estimates (see regression model below).
VE varied with time between vaccination and the outbreak. For
he TUR 11 vaccine VE appeared to decline markedly after 100
ays (Table 2). For the Shamir vaccine, crude VE was  65% [95% CI:
2%–84%] if the outbreak occurred within 50 days of vaccination
ompared to VE = −54% [95% CI: −30% to −80%] and −14% [95%
I: −39% to 6%] if the outbreak occurred 51–100 days and 101–150
ays after vaccination respectively. This effect could not be assessed
n the multivariable analysis due to collinearity.
.4. Regression model
Posterior median VE for the TUR 11 vaccine was 69% [95% cred-
ble interval (95% CI): 50%–81%]. No protective effect was  detected
or the Shamir vaccine (VE = −36% [95% CI: −140%–21%]) (Table 4).
gainst severe disease VE was 83% [95% CI: 67%–92%] for the TUR 11
accine. VE against infection was 63% [95% CI: 29%–81%] for the TUR
1 vaccine. Credible intervals were too wide to interpret the Shamir
accine effect. Cattle from small herds (≤30 cattle) and cattle that
sed common grazing had a greater risk of FMD (Table 4).
Although there was no difference in squared standardised resid-
als in the four different investigations (p = 0.97), model fit did
ary by village (p < 0.0001). Reasons for this were not apparent, but
t may  result from factors not included in the analysis that were
ore important in some villages than others or differences in data
ccuracy, which may  differ by village.
.5. Within-herd incidence and coverage
In the Afyon-1 and Afyon-2 investigations (TUR 11 vaccine), a
ithin-herd incidence >50% only occurred in herds with <75% vac-
ine coverage. In the other TUR 11 study (Denizli province) although
any of the high coverage herds had low incidence, high incidences
up to 100%) occurred in herds with 100% coverage. Outbreaks
n unvaccinated herds always had high incidence (>50%). Unlike
he Shamir investigation, in the TUR 11 investigations within-herd
MD  incidence tended to decline with increasing vaccine coverage
Fig. 3).
able 4
ayesian multivariable regression analysis of vaccine effectiveness against FMD  from field
sed.  Median parameter estimates are presented with credible intervals.
Risk factor Vaccine effectivenes
FMD  
Recently vaccinated TUR 11 vaccine 69% [50%–81%] 
Shamir vaccine −36% [−137% to 22%
Rate ratio
Avoid common grazing 0.2 [0.1–0.36] 
Every  month over 15 months 0.98 [0.977–0.99] 
Herd  size >30 0.25 [0.1–0.5] 
Standard deviation of
random intercept
Herd-group 1.4c
Village 6c
Deviance information criterion 1315 
Chi-sq. goodness of fit test Bayesian p-value 0.2 
a Stopped eating or oral lesions with combined diameter greater than 50% width of har
b Considered infected during the outbreak if FMD  Asia-1 SP antibody titre >32 and posi
c When standard deviations of the random intercept were converted from the complim
30  cattle at common grazing had a mean probability of developing FMD per day of betw
nd  100% for 95% of villages.ne 32 (2014) 1848–1855 1853
In the Shamir investigation, cattle were at grass and group refers
to large grazing groups (16 groups for 32 farms). In the TUR 11
investigations cattle were either permanently housed or housed at
night.
3.6. Post-vaccination immune response
In the Afyon-1 investigation additional cattle were sampled
from a nearby village that did not experience an outbreak but
were vaccinated with the same vaccine batch at approximately the
same time. These 50 sera had mean Asia-1 LPB ELISA titres of 119
(or 102.08) for cattle less than seven months old, 153 (102.18), 237
(102.37) and 206 (102.31) for cattle 7–12 months, 13–24 and over 24
months respectively. The proportion with an Asia-1 SP titre ≥100
(102), a threshold associated with clinical protection, in the differ-
ent age categories (in the same order) was  2/6 (33%), 9/17 (53%),
8/8 (100%) and 15/19 (79%) respectively.
In the outbreak villages, 27/29 (93%) of blood sampled cattle that
were NSP negative and did not have clinical FMD  had an SP LPBE
titre ≥100.
4. Discussion
A single dose of FMD  Asia-1 TUR 11 vaccine was effective at
protecting against clinical disease, VE = 69%, particularly severe
disease, VE = 83%. The vaccine also protected against infection,
VE = 63%. The FMD  Asia-1 Shamir vaccine did not appear to protect,
indicated by (i) the vaccine effectiveness estimate, (ii) the high inci-
dence in vaccinated cattle and (iii) no reduction in incidence until
animals had received >5 doses of vaccine. However, findings for the
Shamir vaccine are based on one investigation.
Although disease enhancement after vaccination has been iden-
tified for some other diseases the negative vaccine effectiveness
for the Shamir vaccine is probably an artefact (residual age-
confounding and collinearity). The confidence intervals show the
uncertainty in the modelled Shamir VE.
It could be argued that outbreaks are cases of vaccine failure that
do not represent typical vaccine performance. If so, vaccine effec-
tiveness estimates would be pessimistic. That said, findings were
consistent with (a) vaccine matching r1-values which suggested a
good match for the homologous TUR 11 vaccine and a poor match
for the Shamir vaccine (see Section 2) and (b) the large number
of outbreaks seen within the Turkish vaccination programme. VE
for the TUR 11 vaccine is comparable with the 60%–85% vaccine
 studies conducted in Turkish villages. A complimentary log–log link function was
s [95% Credible Interval]
Severe FMDa FMD  virus infectionb
83% [67%–92%] 63% [29%–81%]
] −129% [−600% to 21%] 1% [−200% to 68%]
0.1 [0.03–0.27] 0.3 [0.1–0.7]
0.99 [0.98–0.995] 1.03 [1.01–1.04]
0.06 [0.01–0.23] 0.6 [0.2–1.5]
2 2
7 7
832 446
0.1 0.1
d palate.
tive for NSP antibodies.
entary log–log scale an unvaccinated individual, ≤15 months age, from a herd of
een 0.1% and 40% for 95% of herds. Between villages this figure varied between 0%
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Fig. 3. Relationship between within-herd vaccine coverage (i.e. the percentage of animals vaccinated with the FMD  Asia-1 vaccine at the round of vaccination prior to the
outbreak) and within-herd attack rate (i.e. the percentage of animals with clinical FMD  during the outbreak) for cattle over four months of age for all households. The solid
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fficacy that would be expected for a 3PD50 vaccine [14] and is close
o OIE batch release requirements where >70%–75% of vaccinated
attle must have a protective titre [13].
When comparing the Shamir and TUR 11 vaccines, differences in
E are consistent with differences in vaccine match r1-values. The
losest we had to a direct comparison of the two  vaccines was in
fyon-1 where 11 doses of Shamir vaccine were used in one village
hilst TUR 11 vaccine was used in the other investigated village.
he TUR 11 vaccine was approximately twice as effective with 3/11
27%) affected in cattle vaccinated with the Shamir vaccine and
1/80 (14%) in the TUR 11 vaccinated cattle (see Table 2), however,
his comparison was under-powered.
TUR 11 vaccine performance varied, possibly due to variability
n (1) field conditions, e.g. season, time since vaccination, coverage,
usbandry, body condition, nutrition and other animal factors; (2)
accine potency at point of production; or (3) vaccine delivery (e.g.
old chain or shelf life adherence).
The reduction in VE with increasing time since vaccination was
s expected, with protection due to the TUR 11 vaccine declining
fter 100 days. The Shamir VE appeared to decline sooner (after 50
ays) (Table 2).
The findings differ to those from a PD50 challenge study. A high
otency (>6PD50) Shamir vaccine held in the EU vaccine bank pro-
ected against clinical FMD  when challenged with the Turkish FMD
sia-1 Sindh-08 field virus [15]. Differences in protection will partly
eflect differences in potency as poor vaccine match may  be over-
ome if high potency vaccines are used [16] and in the challenge
tudy the vaccine used was likely to be much greater than 6PD50.
urthermore, in the challenge study, animals were assessed at time
f peak immunity (21 days after vaccination), whereas in the VE
tudy time between vaccination and challenge varied from one to
ve months.NSP serology is a sensitive method of detecting animals with
ignificant systemic viral replication [17]. As this will correlate
ith virus shedding, NSP status is a suitable outcome for vaccine
valuation. S¸ ap institute vaccines are quality controlled for NSPks except in the Ardahan investigation where the FMD  Asia-1 Shamir vaccine was
purity, however, NSP sero-positivity following multiple vaccine
doses can occur. Including age in the model helped control for this.
NSP sero-status was considered together with Asia-1 SP sero-status
to increase specificity. Cross-reactivity between SP antibodies of
different serotypes could lead to falsely classifying animals with
prior A or O infections as infected during the investigated Asia-1
outbreak, however, no recent prior outbreaks had occurred.
For twelve months after the loss of maternal immunity (ages
7–18 months) animals were particularly susceptible to FMD. As this
age group are frequently traded, they should be targeted by control
measures as a high risk group.
FMD  is one of the most infectious animal pathogens with esti-
mates for the basic reproduction number (R0) within a herd ranging
from 2 to 70 [18]. Furthermore, husbandry practices mean that
villages in Turkey can be considered a well-mixed population
equivalent to a herd. According to herd-immunity theory [19],
with 69% VE and coverage levels found during these investiga-
tions vaccination could suppress within-village outbreaks with an
R0 < 1.4 for Afyon-1 (coverage = 42%) up to R0 < 2.25 for Denizli (cov-
erage = 83%). With 100% coverage the vaccine could control an
outbreak with R0 < 3.2. An inability to control outbreaks with FMD
vaccines has been reported before [18].
Although there are limitations with this sort of calculation, it
indicates that additional sanitary measures are required to reduce
virus exposure and R0 to a level that will not overwhelm vaccine
protection. Routine culling is not feasible in highly endemic regions
leaving improved biosecurity, particularly isolation of infected and
high risk premises, as the best option. Not surprisingly use of com-
munal grazing was an important risk factor.
Although there is less contact between animals in adjacent vil-
lages, common grazing usually overlaps. With high attack rates
(35% in TUR 11 vaccinated cattle) and large numbers of cattle per
village (≥450 cattle), each infected village will contain >100 dis-
eased cattle. When relying on vaccination alone, transmission by
one or more infected animals to neighbouring villages or livestock
markets seems likely.
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. Conclusion
In this study we found that the FMD  Asia-1 TUR 11 vaccine pro-
ided reasonable protection against disease and infection with the
omologous field virus. However, vaccine performance varied from
arm to farm. Although the vaccine performed as expected for a
tandard potency FMD  vaccine [13], widespread transmission still
ccurred, partly due to limited vaccine coverage. However, there is
 mismatch between the very high vaccine effectiveness required to
ontrol FMD  and the actual effectiveness of standard FMD  vaccines.
he use of other control measures in conjunction with vaccination
ill help to overcome this mismatch.
The FMD  Asia-1 Shamir vaccine did not appear to protect in the
utbreak investigated.
Vaccine effectiveness should be monitored, particularly when
here are outbreaks within a vaccinated population.
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